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    1) The early administration of folic acidantagonist, Methotrexate, for lethally gamma-
 irradiated mice treated with HBM is highly effective for the suppression against the de-
 velopment of the homologous disease, but its effect is still less than that of the IBM treat-
 ment. 
  2) The early administration of Methotrexate for the lethally gamma-irradiated mice 
 treated with the homologous spleen cells is not enough effective for the suppression of the 
 homologous disease. 
   3) The probable mechanism as to the suppression of the immune response by the admini-
 stration of Methotrexate was discussed. 
                          INTRODUCTION 
   Mice exposed to lethal total body irradiation which receive an intravenous 
inoculation of the homologous bone marrow (HBM) may survive acute irradia-
tion death. Later, the majority of them may die from so-called homologous 
disease. It is generally accepted that there is an immune response between 
host and graft. Therefore, in order to inhibit the homologous disease, the use 
of immunological tolerated fetal liver as a protective agent in place of adult 
HBM has been studied, but its effect seems to be not always enoughl`41. Drug 
treatment as a method of modifying the homologous disease has been tried. 
Uphoffb' reported that the use of folic acid antagonist, Methotrexate, might 
spare mice that would normally succumb to a homograft reaction following 
lethal total body X irradiation and HBM treatment. Ferrebee et al.6 5 also re-
ported that an early administration of Methotrexate prevented the delayed 
foreign marrow reaction. We have been working also several years for the 
suppression of the homologous disease. The results obtained by the use of 
Methotrexate up to the present time are to be reported here. 
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                                MATERIALS AND METHODS 
Dd/s and Na2 strain mice were used as recipients and donors. They were 
           supplied from the Kyoto University Animal Center. A Co" gamma-irradiation 
          facility which belongs to the Institute for Chemical Research of Kyoto Univer-
           sity was used in the present experiment. The conditions of irradiation were 
           described elswhere9710). Lethal irradiation in this study means approximately 
          900 r irradiation which is 100% lethal to mice within 30 days. We have LD100 
           dose of gamma-rays to mice in less than half a minute. Methotrexate (1.5 mg 
          per kg body weight) was injected intraperitoneally 4 times every other day, 
          biginning 1 day after the total-body irradiation and HBM transplantation. In 
          one group, Methotrexate was given 8, 10, 12 and 14 days after the irradiation 
           and HBM transplantation. Non-irradiated mice which were injected Methotre-
          xate with the same dose and duration did not show any signs of toxicity due 
           to this drug. There were found no changes in the peripheral blood pictures 
           and body weight'°. 
              The number of the nucleated cells of inoculated bone marrow and spleen 
           cell suspension was 10x 106, respectively. 
                               RESULTS AND DISCUSSIONS 
              Eight types of experiments were carried out, as summarized in Table 1. 
              In the experiment 1, Methotrexate was given at 1, 3, 5 and 7 days to mice 
          irradiated and treated with HBM. In this group of experiment, the survival 
          rates were 78% at 21 days and 73% at 30 days. It should be noted that they 
                 Table 1. Survival of gamma-irradiated mice treated with homologous bone marrow 
                    and homologous spleen cells. 
                                             Number of survival at days) 
oo Survival (at days)             Type of Experiments Number of irradiated)  
                              7 14 21 30 60  90 21 30 60  90 
          1) HBM+MT*22/22 20/22 17/22 16/22 10/22 7/22 78 73 45 32 
(1,3,5 and 7 days after irrad.) 
          2) HBM+MT**16/16 12/16 9/16 9/16 4/16 4/16 51 51 25 25 
            (8,10,12 and 14 days after irrad.) 
         3) HSC -MT26/32 13/32 10/31 8/30 3/29 0/29 33 26 10 0 
(1,3,5 and 7 days after irrad.) 
          4) HSC+MT31/32 31/32 19/32 14/32 7/32 7/32 59 44 22 22 
(1,3,5 and 7 days after irrad.) 
        5) HBM6/10 3/10 3/10 2/10 1/10 1/10 30 20 10 10 
        6) HSC17/20 13/20 7/20 2/20 1/20 1/20 35 10 5 5 
        7) ISC+MT8/8 7/8 7/8 7/8 7/8 7/8 88 88 88 88 
(1,3,5 and 7 days after irrad.) 
       8) ISC8/8 8/8 8/8 7/8 7/8 7/8 100 88 88 88 
Number of nucleated cells was 10><106.— 
                * MT: 1.5 mg/lcg of Methotrexate given at 1, 3, 5 and 7 days after Irradiation. 
               ** MT: 1.5 mg/kg of Methotrexate given at 8, 10, 12 and 14 days after Irradiation. 
HBM: Homologous bone marrow. HSC: Homologous spleen cells. 
ISC: Isologous spleen cells. 
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   Fig. 1. Body weight changes in mice irradiated lethally and treated with homologous 
     bone marrow and Methotrexate. 
     Body weight change to preirradiation level was represented in percentage. 
were much better than those of 30% at 21 days and 20% at 30 days in HBM 
treatment alone in experiment 5. Body weight changes in both group are 
shown in Fig. 1. They reached almost pre-irradiation level approximately 20 
days after the total-body irradiation and, then decreased later again. The 
mice treated with HBM alone, however, showed more rapid decreasing tendency 
than the mice treated with HBM and Methotrexate did, although the survival 
rates in the latter group also decreased to 45% at 60 days. These results may 
suggest the possibility that an immune response was suppressed by early ad-
ministration of Methotrexate for about 30 days, though it occurred in some 
mice later. 
   Ferrebee et al.6) recently discussed that, if the reaction of immunnological-
ly competent cells in the marrow infusion can be restrained during a short 
interval, either these cells pass through their life-span and die without injur-
ing the host, or they and their progeny acquire tolerance to their environment 
without first having injured it and themselves by reaction. Our results can be 
also explained with this idea. 
Uphoff°' reported that the secondary weight loss which might be caused by 
the homograft response was suppressed by the administration of Methotrexate 
every other day 9 times beginning at 14 days after the total-body irradiation. 
But the other workers') reported that the survival rates of mice treated with 
HBM and the delayed administration of Methotrexate were 90% at 10 days and 
20% at 30 days. As shown in experiment 2, when Methotrexate was given at 
8, 10, 12 and 14 days after irradiation, the survival rates were 51%, 51% and 25% 
at 21, 30 and 60 days after the irradiation, respectively. These results are not 
better than those in experiment 1, but a little better than those in HBM treat-
ment alone. 
   It is well known that the spleen cells can protect the mice irradiated 
lethally, but it is also believed, so far, that there are many lymphoreticular 
cells in the spleen of mice, but almost nothing of them in the bone marrow. 
These facts led us to presume that the effect of Methotrexate must diminish 
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           when the number of the transplanted immunological competent cells increases, 
           and the following experiments were undertaken. Isologous spleen cell trans-
           plantation with and without Methotrexate are shown in experiments 7 and 8, 
           respectively. The survival rates in both groups were almost the same. There-
           fore, it goes without saying that this dose of Methotrexate used has not any 
           marked toxicity at all in lethally gamma-irradiated mice, while Uphoffu sug-
           gested that Methotrexate might be more toxic in the lethally irradiated mice 
           than in normal mice. In the homologous spleen cell plus Methotrexate treated 
           group, body weight began to decrease again about 20 days after the irradiation 
           and did not show any tendency of recovery, as shown in Fig. 2. As described 
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                Fig. 2. Body weight changes in mice irradiated lethally and treated with homologous 
                   spleen cells and Methotrexate. 
                   Body weight change to preirradiation level was represented in percentage. 
           above, the immunological competent cells seem to be reactive in the early 
           stage of recovering after the gamma-irradiation, and it is probable that, the 
           more the number of them is, the stronger the immune response occurs. When 
           Methotrexate with the dose of demonstrating no toxicity is administered to 
          mice treated with HBM transplantation, it is thought to be highly effective for 
           the suppression against the development of the homologous disease, but the 
           effect is still less than that of the IBM treatment. These results show the 
           limitation of the usefulness of Methotrexate. Further investigations in order 
            to prevent the immune response are awaited. 
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